Skip to main content

Table 1 Clinicopathologic data for all patients with gastric cancer (n = 30)

From: Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker

  Patients sCD26 levels (pg/mL) p value
Tumor location n (%)    
 Upper 6 (20 %) 556.1 ± 77.2 0.986
 Middle 11 (36.6 %) 558.0 ± 133.8  
 Lower 13 (43.4 %) 564.2 ± 108.5  
Tumor size n (%)    
 <3 cm 15 (50 %) 569.1 ± 101.2 0.800
 >3 cm 15 (50 %) 558.5 ± 121.6  
Lauren’s Type n (%)    
 Intestinal 20 (60 %) 564.8 ± 94.8 0.934
 Diffuse 10 (40 %) 651.0 ± 145.9  
Differentation n (%)    
 well 4 (13.3 %) 556.3 ± 95.4 0.681
 moderately 20 (66.7 %) 553.9 ± 120.0  
 poorly 6 (20 %) 559.8 ± 107.2  
Tumor status n (%)    
 T1a 0 - 0.781
 T1b 2 (6.6 %) 556.3 ± 0  
 T2 6 (20 %) 563.4 ± 88.1  
 T3 12 (40 %) 543.5 ± 146.9  
 T4a 7 (23.3 %) 636.7 ± 0  
 T4b 3 (10 %) 579.6 ± 88.9  
Lymph node metastasis n (%)    
 N0 12 (40 %) 602.8 ± 120.1 0.113
 N1 8 (40 %) 511.3 ± 50.6  
 N2 4(6.6 %) 447.7 ± 109.2  
 N3a 2 (10 %) 660.2 ± 0  
 N3b 4 (3.4 %) 636.7 ± 0  
Metastatic disease n (%)    
 M0 26 (86.7 %) 562.0 ± 114.7 0.660
 M1 4 (13.3 %) 586.2 ± 83.5  
Stage n (%)    
 Ia 1 (3.4 %) 546.1 ± 26.5 0.513
 Ib 4 (13.3 %) 587.2 ± 81.3  
 IIa 2 (6.6 %) 603.3 ± 144.3  
 IIb 1 (3.4 %) 626.8 ± 101.8  
 IIIa 8 (26.6 %) 587.1 ± 59.7  
 IIIb 5 (16.7 %) 613.8 ± 150.4  
 IIIc 5 (16.7 %) 564.8 ± 119.7  
 IV 4 (13.3 %) 518.9 ± 70.4  
Resection type n (%)    
 R0 25 (83.3 %) 562.0 ± 114.7 0.660
 R1-2 5 (16.7 %) 586.2 ± 83.5  
HER2 n (%)    
 positive 15 (50 %) 511.8 ± 84.8 0.006
 negative 15 (50 %) 619.1 ± 109.9